NOT FOR DISTRIBUTION
Header cover image

Market Cap

HK$3.1b

Last Updated

2021/04/11 10:19 UTC

Data Sources

Company Financials +

Executive Summary

Essex Bio-Technology Limited, an investment holding company, develops, manufactures, distributes, and sells biopharmaceutical products in the People’s Republic of China and internationally. More Details


Snowflake Analysis

Excellent balance sheet and good value.

Share Price & News

How has Essex Bio-Technology's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 1061 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: 1061's weekly volatility (11%) has been stable over the past year.


Market Performance


7 Day Return

2.9%

1061

-3.1%

HK Biotechs

-1.1%

HK Market


1 Year Return

18.0%

1061

59.2%

HK Biotechs

28.6%

HK Market

Return vs Industry: 1061 underperformed the Hong Kong Biotechs industry which returned 63.8% over the past year.

Return vs Market: 1061 underperformed the Hong Kong Market which returned 29.2% over the past year.


Shareholder returns

1061IndustryMarket
7 Day2.9%-3.1%-1.1%
30 Day-6.6%2.0%-1.8%
90 Day39.0%7.1%3.4%
1 Year19.2%18.0%59.5%59.2%33.5%28.6%
3 Year-34.7%-36.6%-32.1%-33.3%4.0%-6.9%
5 Year33.5%27.2%-0.3%-4.0%48.7%23.7%

Long-Term Price Volatility Vs. Market

How volatile is Essex Bio-Technology's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Essex Bio-Technology undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 1061 (HK$5.38) is trading below our estimate of fair value (HK$34.86)

Significantly Below Fair Value: 1061 is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 1061 is good value based on its PE Ratio (14.2x) compared to the HK Biotechs industry average (38.8x).

PE vs Market: 1061 is poor value based on its PE Ratio (14.2x) compared to the Hong Kong market (11.7x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 1061's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 1061 is good value based on its PB Ratio (2.2x) compared to the HK Biotechs industry average (3.4x).


Future Growth

How is Essex Bio-Technology forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

17.6%

Forecasted annual revenue growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 1061's forecast earnings growth is above the savings rate (1.5%).

Earnings vs Market: Insufficient data to determine if 1061's earnings are forecast to grow faster than the Hong Kong market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 1061's revenue (17.6% per year) is forecast to grow faster than the Hong Kong market (13.4% per year).

High Growth Revenue: 1061's revenue (17.6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 1061's Return on Equity is forecast to be high in 3 years time (29.6%)


Past Performance

How has Essex Bio-Technology performed over the past 5 years?

17.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 1061 has a high level of non-cash earnings.

Growing Profit Margin: 1061's current net profit margins (22.4%) are lower than last year (23.6%).


Past Earnings Growth Analysis

Earnings Trend: 1061's earnings have grown by 17.5% per year over the past 5 years.

Accelerating Growth: 1061's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 1061 had negative earnings growth (-27.5%) over the past year, making it difficult to compare to the Biotechs industry average (17.5%).


Return on Equity

High ROE: 1061's Return on Equity (15.4%) is considered low.


Financial Health

How is Essex Bio-Technology's financial position?


Financial Position Analysis

Short Term Liabilities: 1061's short term assets (HK$1.3B) exceed its short term liabilities (HK$606.0M).

Long Term Liabilities: 1061's short term assets (HK$1.3B) exceed its long term liabilities (HK$389.1M).


Debt to Equity History and Analysis

Debt Level: 1061's debt to equity ratio (38.9%) is considered satisfactory.

Reducing Debt: 1061's debt to equity ratio has increased from 12.9% to 38.9% over the past 5 years.

Debt Coverage: 1061's debt is well covered by operating cash flow (53.9%).

Interest Coverage: 1061 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Essex Bio-Technology current dividend yield, its reliability and sustainability?

0.93%

Current Dividend Yield


Upcoming Dividend Payment

TodayApr 11 2021Ex Dividend DateMay 14 2021Dividend Pay DateJun 01 202118 days from Ex DividendBuy in the next 32 days to receive the upcoming dividend

Dividend Yield vs Market

Notable Dividend: 1061's dividend (0.93%) isn’t notable compared to the bottom 25% of dividend payers in the Hong Kong market (1.96%).

High Dividend: 1061's dividend (0.93%) is low compared to the top 25% of dividend payers in the Hong Kong market (5.97%).


Stability and Growth of Payments

Stable Dividend: 1061's dividend payments have been volatile in the past 10 years.

Growing Dividend: 1061's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its low payout ratio (13.2%), 1061's dividend payments are thoroughly covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

20.3yrs

Average management tenure


CEO

Haizhou Fang (54 yo)

no data

Tenure

HK$2,477,422

Compensation

Mr. Haizhou Fang serves as the Managing Director and Executive Director of Essex Bio-Technology Limited and served as its General Manager. Mr. Fang is qualified as a Senior Pharmaceutical Engineer (Profess...


CEO Compensation Analysis

Compensation vs Market: Haizhou's total compensation ($USD225.20K) is about average for companies of similar size in the Hong Kong market ($USD313.12K).

Compensation vs Earnings: Haizhou's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: 1061's management team is seasoned and experienced (20.3 years average tenure).


Board Members

Experienced Board: 1061's board of directors are seasoned and experienced ( 16.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Essex Bio-Technology Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Essex Bio-Technology Limited
  • Ticker: 1061
  • Exchange: SEHK
  • Founded: 1990
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: HK$3.102b
  • Shares outstanding: 576.51m
  • Website: https://www.essexbio.com

Number of Employees


Location

  • Essex Bio-Technology Limited
  • No. 88 Keji 6th Road
  • Hi-Tech Zone
  • Zhuhai
  • Guangdong Province
  • China

Listings


Biography

Essex Bio-Technology Limited, an investment holding company, develops, manufactures, distributes, and sells biopharmaceutical products in the People’s Republic of China and internationally. The company ope...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/04/11 10:19
End of Day Share Price2021/04/09 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.